ArticleHeart and vessels2025
Effect of heparin anticoagulation on the antithrombogenicity of an extracorporeal membrane oxygenation system under veno-arterial bypass in an animal model.
Article in Heart and vessels, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
An extracorporeal membrane oxygenation (ECMO) system consisting of a heparin-coated membrane oxygenator with polymethylpentene hollow fiber membranes and a heparin-coated hydrodynamically levitated centrifugal pump was developed. The effect of heparin anticoagulation on the antithrombogenicity of the ECMO system under veno-arterial bypass was evaluated in an animal model. Veno-arterial bypass with the ECMO system was induced in goats. Ten goats were evaluated which were divided into heparin anticoagulation-free (HPF; n = 5) and heparin anticoagulation (HP; n = 5) groups. Evaluation of the ECMO system focused on thrombus formation and changes in blood test data. Veno-arterial bypass with the ECMO system was maintained for 2 weeks in both groups. The extent of thrombus formation in the oxygenators was suppressed in the HP group. The centrifugal pumps were free of major thrombus formation in both groups. From baseline to postoperative day (POD) 1, both groups showed significant decreases in platelet counts, with a significant reduction in von Willebrand factor (vWF) activity levels in the HPF group. Between PODs 1 and 14, POD differences were observed in platelet counts without group or interaction differences. The levels of vWF activity showed significant group differences, with the HPF group demonstrating lower values than the HP group, but no significant POD or interaction differences. Veno-arterial bypass with the ECMO system was sustained for 2 weeks regardless of heparin anticoagulation. Heparin anticoagulation suppressed the extent of thrombus formation in the oxygenators. The centrifugal pumps were free of major thrombus formation regardless of heparin anticoagulation.
Indexed as
Identifiers
40715847What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.